The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
 
Wen Wee Ma
Consulting or Advisory Role - Wellstat Therapeutics (Inst)
Research Funding - Actuate Therapeutics (Inst); Athenex (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merrimack (Inst); Sun Pharma (Inst)
 
Tyler J. Zemla
No Relationships to Disclose
 
Daniel Walden
No Relationships to Disclose
 
Robert R. McWilliams
Stock and Other Ownership Interests - Zentalis
Consulting or Advisory Role - Merrimack (Inst); Newlink Genetics (Inst); Zentalis
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst)
 
Walid Labib Shaib
Honoraria - Blueprint Medicines; BMS; Ipsen; Lexicon; Mylan; Natera
Research Funding - ArQule (Inst); Basilea (Inst); GlaxoSmithKline (Inst); Lexicon (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Lexicon
 
Daniel H. Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer
 
Bassel F. El-Rayes
Honoraria - Charles River Associates
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Exelixis; Genentech; QED Therapeutics; QED Therapeutics; Seagen; Stemline Therapeutics; Taiho Oncology; Taiho Oncology
Speakers' Bureau - Intellisphere
Research Funding - Adaptimmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); IQvia (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Wayne State University (Inst); Xencor (Inst); Zymeworks (Inst)
Other Relationship - ERYTECH Pharma; Exelixis; SC Liver Research Consortium
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Curium Pharma; Ipsen (Inst); Lexicon (Inst); ScioScientific; TERUMO
Research Funding - Advanced Accelerator Applications (Inst); Agios (Inst); Basilea (Inst); Ipsen (Inst); Novartis (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
 
Timothy J. Hobday
No Relationships to Disclose
 
Sarah Bruggeman
No Relationships to Disclose
 
Brandy L. Jaszewski
No Relationships to Disclose
 
Fang-Shu Ou
Consulting or Advisory Role - SC Liver Research Consortium
 
Christina Wu
Honoraria - Oncology Learning Network; PrecisCA
Consulting or Advisory Role - Array BioPHarma; Natera; Nova Research Company
Research Funding - Boston Biomedical (Inst); InhibRx (Inst); Lycera (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network